76714-45-9

Upstream product

• 1567-75-5 1-(1-methylcyclopropyl)ethanone 

Downstream Products

• 1218773-31-9 C₁₆H₂₁NO₃S 

Relevant academic research and scientific papers

Five-membered heteroaromatic ring derivative, preparation method thereof, pharmaceutical composition and application thereof

The invention discloses a five-membered heteroaromatic ring derivative, a preparation method thereof, a pharmaceutical composition and application thereof. The five-membered heteroaromatic ring derivative (I), isomers, prodrugs, stable isotope derivatives or pharmaceutically acceptable salts thereof have the following structure. The five-membered heteroaromatic ring derivative has a good IDO inhibitory effect, and can effectively treat, relieve and/or prevent various related diseases such as tumors, virus infection or autoimmune diseases, and the like caused by immunosuppression.

DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a dimethyl-nonatetraenyl-trimethyl-cyclohexyl structure useful as therapeutics for the treatment of subjects suffering fro

INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2

The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N or C (but both not N) and R1-R3 are as defined herein.

INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y1 represents a C1-6 alkylene group or the like; Y2 represents a single bond or the like; Z represents —C(═O)—NHSO2R6, an acidic 5-membered hetero ring group, or the like; R1 represents a hydrogen atom or the like; R2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS

The present invention relates to compounds of the Formula (I), wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS

This invention provides a compound of the formula (I): wherein Rl represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group in R3 is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α are selected from the group consisting of aryl groups, hydroxy groups, oxo groups, etc.; said aryl groups have 6 to 10 carbon atoms; said aryl groups are unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic groups and heterocyclic moiety in heterocycliccarbonyl groups are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, etc.; or a pharmaceutically acceptable amide of such compound, or a pharmaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

Cycloalkyl (α-triazolyl-β-hydroxy)-ketones as fungicides and plant growth regulators

Cycloalkyl (α-triazolyl-β-hydroxy)-ketones of the general formula STR1 in which R1 represents an optionally substituted cycloalkyl group, and R2 represents a halogenoalkyl, halogenoalkenyl or alkoxycarbonyl group, and their physiologically acceptable acid addition salts and metal salt complexes are new, are prepared as described and find use as fungicides and plant growth regulators.